Human T lymphotropic virus 1
Conditions
Interventions
40 individuals will be recruited. All research participants will be treated with physiotherapy and will receive baclofen tablets (daily use of 3 10mg tablets for three months). They will be divided in
Drug
Biological/vaccine
Other
Sponsors
Hospital Universitário Professor Edgard Santos
Hospital Universitário Professor Edgard Santos
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals over 18 years old; both sexes; diagnosed with tropical spastic paraparesis, confirmed with Elisa and Western Blot tests; who have not used botulinum toxin to treat spasticity
Exclusion criteria
Exclusion criteria: individuals who are pregnant; bleeding disorders; with an infectious skin lesion at the injection site; other neurological diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spasticity, assessed by the Modified Ashworth Scale before and after 12 weeks of intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Functionality, assessed by the Functional Independence Measure before and after 12 weeks of intervention;Quality of life, assessed by the Short Form Health Survey (SF-36) before and after 12 weeks of intervention;Gait speed, assessed using the 10-meter walk test before and after 12 weeks of intervention;Functional mobility, assessed using the Timed Up and Go Test (TUG) before and after 12 weeks of intervention;Muscle strength of lower limbs will be assessed by the five repetition sit / stand test before and after 12 weeks of intervention;Pain intensity and location, assessed by the Visual Analogue Scale and the Michigan Body Map, respectively, before and after 12 weeks of intervention;Activity and social participation, assessed by the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 before and after 12 weeks of intervention | — |
Countries
Brazil
Contacts
Public ContactAilton Melo
Hospital Universitário Professor Edgard Santos
Outcome results
None listed